Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes

Figures & data

Figure 1 Optical coherence tomography scans in a case of branch retinal vein occlusion (eye 2).

Note: The scans demonstrate decreased macular edema after 2-week administration of tranexamic acid and the deterioration at the 6-week time point.
Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness (μm); ILM, internal limiting membrane; LogMAR, logarithm of minimum angle of resolution.

Table 1 Retinal vein occlusion patient characteristics and results

Patients/eye	Lateral	Age (years)	Gender	Etiology	Duration of ME (months)	Type of ME	BCVA (logMAR)			CMT (µm)			Previous treatment
							Baseline	2 weeks	6 weeks	Baseline	2 weeks	6 weeks
1/1	OS	66	M	BRVO	58	RS, CME	0.52	0.7	0.52	633	561	609	6IVB
2/2	OS	67	M	BRVO	27	RS, CME, SRD	0.3	0.22	0.22	408	332	389	1STTA, PC
3/3	OD	77	M	CRVO	36	RS, CME, SRD	0.3	0.3	0.7	608	575	615	2IVB, 1IVA, 2STTA
4/4	OD	52	F	BRVO	11	RS, CME, SRD	0.52	0.52	0.52	441	430	340	2IVR, 1IVA
5/5	OS	83	M	BRVO	11	RS, CME	0.15	0.15	0.05	344	309	356	2IVR
6/6	OS	72	M	CRVO	90	RS	0.1	0.1	0.15	327	331	324	2IVB
7/7	OD	74	M	CRVO	47	CME	0.22	0.22	0.4	513	463	523	1IVB, 1IVR, 1IVA
Mean	70.1±9.89			40.0±28.1		0.30±0.17	0.32±0.22	0.37±0.23	467.7±121.4	428.7±110.5	450.9±128.0
p-value							0.87	0.58		0.024	0.49

Abbreviations: BCVA, best-corrected visual acuity; BRVO, branch retinal vein occlusion; CME, cystoid macular edema; CMT, central macular thickness; CRVO, central retinal vein occlusion; IVA, intravitreal injection of aflibercept; IVB, intravitreal injection of bevacizumab; IVR, intravitreal injection of ranibizumab; logMAR, logarithm of minimum angle of resolution; ME, macular edema; PC, photocoagulation; RS, retinal swelling; SRD, serous retinal detachment; STTA, sub-tenon injection of triamcinolone acetonide.

Table 2 Diabetic macular edema patient characteristics and results

Patients/eye	Lateral	Age (years)	Gender	Duration of ME (months)	Type of ME	BCVA (logMAR)			CMT (µm)			Previous treatment
						Baseline	2 weeks	6 weeks	Baseline	2 weeks	6 weeks
1/1	OD	74	F	41	RS, CME	0.82	0.7	1	789	686	699	2IVB, 1STTA
1/2	OS	74	F	41	RS, CME	0.3	0.52	0.7	450	345	336	1STTA, vitrectomy
2/3	OD	66	F	30	RS, SRD	0.7	0.52	0.52	679	562	550	2IVR, 2IVA, 1STTA
3/4	OD	64	F	14	RS	0.52	0.52	0.4	424	383	370	1STTA, PC
4/5	OS	69	F	44	RS	0.3	0.3	0.15	334	330	315	3IVR, PC
5/6	OD	47	F	28	RS, CME, SRD	0.4	0.22	0.4	510	557	563	2STTA, PC, 1IVA
5/7	OS	47	F	28	RS, CME, SRD	0.52	0.52	0.52	673	671	627	3STTA, PC, 1IVA
Mean		63.0±11.5		32.3±10.5		0.51±0.20	0.47±0.16	0.53±0.27	551.3±164.8	504.9±151.3	494.3±152.7
p-value							0.71	0.96		0.12	0.063

Abbreviations: BCVA, best-corrected visual acuity; CME, cystoid macular edema; CMT, central macular thickness; IVA, intravitreal injection of aflibercept; IVB, intravitreal injection of bevacizumab; IVR, intravitreal injection of ranibizumab; logMAR, logarithm of minimum angle of resolution; ME, macular edema; PC, photocoagulation; RS, retinal swelling; SRD, serous retinal detachment; STTA, sub-tenon injection of triamcinolone acetonide.